<DOC>
	<DOC>NCT00634452</DOC>
	<brief_summary>To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).</brief_summary>
	<brief_title>Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Diagnosis of CD30positive HL by immunohistochemistry or flow cytometry Must have failed or relapsed following second line chemotherapy or radiation or failed/relapsed following autologous stem cell transplant Bimeasurable disease ECOG Performance Status of 0 2 Meet all screening laboratory values Previous treatment with any other antiCD30 antibody History of allogeneic transplant Any tumor lesion greater than or equal to 10 cm in diameter Any active or chronic significant infection Underlying medical condition which will make the administration of MDX 1401 hazardous Concomitant corticosteroids, chemotherapy, investigational agents, other antiHL biologics, or radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hodgkin's</keyword>
	<keyword>Cancer</keyword>
	<keyword>bi-measurable disease</keyword>
	<keyword>Lymphoma</keyword>
</DOC>